Normal Human Immunoglobulin (CSL Behring)(Normal Human Immunoglobulin (CSL Behring)) - 在研适应症：继发性免疫缺陷，获得性免疫缺陷综合征，丙种球蛋白缺乏血症_专利_临床

概要

基本信息

药物类型

免疫球蛋白

别名

Freeze-dried pH4 treatedhuman immunoglobulin、IgG、Immune Globulin Intravenous (Human) (CSL Behring)

+ [22]

靶点-

作用方式-

作用机制-

治疗领域

免疫系统疾病感染神经系统疾病+ [5]

在研适应症

继发性免疫缺陷获得性免疫缺陷综合征丙种球蛋白缺乏血症+ [6]

非在研适应症

急性缺血性卒中非布鲁顿型无丙种球蛋白血症Bruton型无丙种球蛋白血症+ [13]

原研机构

CSL Behring LLC

在研机构

CSL Behring GmbH

CSL Behring LLCCSL Behring AG

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2000-07-27),

原发性免疫缺陷疾病免疫性血小板减少症

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

关联

70

项与 Normal Human Immunoglobulin (CSL Behring) 相关的临床试验

NCT06524739

/ Recruiting临床3期

Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA®) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)

This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of IgPro20 in participants with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome (post-Coronavirus Disease 2019 [COVID-19] POTS [post-COVID-POTS]).

开始日期2024-08-28

申办/合作机构

CSL Behring LLC

NCT05193552

/ Recruiting临床4期IIT

A Prospective Study of the Utility of Spirometry to Identify and Manage Immunoglobulin Replacement Dosage in Primary Antibody Deficiency in Patients with Potentially Reversible Airway Disease

Although there is evidence in the literature that gammaglobulin replacement therapy can lead to a reduction in the prevalence of pulmonary infection and improved lung function, there is no published study to guide immunologists regarding the use of spirometry in titrating IG therapy to assist in the management of immunodeficiency patients with regards to gammaglobulin replacement therapy.
The investigators propose to study the use of spirometry to identify patients that could potentially benefit from an increase in IGRT. The investigators will identify 22 common variable immune deficiency (CVID) study subjects on stable IGRT replacement therapy equivalent to 0.40 to 0.60 gm/kg per 4 weeks who have evidence of mild to moderate obstruction as assessed by an FEF25-75% between 50% and 80% of predicted. Patients who are on Hizentra will be preferentially recruited. Of these 22, 11 will be identified at random and treated for 6 months at their current dose (control population). The remaining 11 study subjects (treatment group) will have their level of IGRT increased by the equivalent of 0.05 gm/kg in dose per 4 weeks, adjusted for bioavailability as per manufacturer's instructions. On average, rounded up to the nearest gram, this will typically increase their dose of Hizentra by 2 gm per week.

开始日期2024-01-15

申办/合作机构

The University of Alabama at Birmingham

NCT05614128

/ RecruitingN/AIIT

Validation of Cutaneous Nerve Demyelination in Diagnosis and Treatment of CIDP

The goal of this observational study is to learn about chronic inflammatory demyelinating polyneuropathy. The main question the investigators would like to answer is 1) can skin biopsy identify demyelination better than nerve conduction studies (electrical tests of the nerves)? and 2) how do nerves improve after treatment in CIDP? Participants will be asked to undergo skin biopsy of the finger at baseline and at 3 months and 6 months after treatment with IVIG (which is the FDA approved treatment for CIDP).

开始日期2023-02-28

申办/合作机构

Vanderbilt University Medical Center

[+1]

100 项与 Normal Human Immunoglobulin (CSL Behring) 相关的临床结果

登录后查看更多信息

100 项与 Normal Human Immunoglobulin (CSL Behring) 相关的转化医学

登录后查看更多信息

100 项与 Normal Human Immunoglobulin (CSL Behring) 相关的专利（医药）

登录后查看更多信息

1,057

项与 Normal Human Immunoglobulin (CSL Behring) 相关的文献（医药）

2025-03-01·IN VIVO

Renal Expression Levels of C5a Receptor and Autophagy-related Beclin-1 and LC3A/B Are Simultaneously Enhanced Under Immunoglobulin Treatment in a Rat Model of Sepsis

Article

作者: Koral, Gizem ; Orhun, Gunseli ; Polat, Özlem ; Esen, Figen ; Anakli, Ilkay ; Yilmaz, Vuslat ; Canbaz, Mert ; Ulusoy, Canan ; Tüzün, Erdem ; Ozcan, Perihan Ergin

BACKGROUND/AIM:

Sepsis-induced acute kidney injury is a fatal, potentially reversible clinical condition. C5a receptor (C5aR) has been implied to play pivotal roles in both autophagy and sepsis-induced organ dysfunction. The aim of this study was to demonstrate the effects of intravenous immunoglobulin preparations on the expression of autophagy markers and investigate possible association between C5aR expression and autophagy in the kidney tissue of septic rats.

MATERIALS AND METHODS:

Sepsis was induced by cecal ligation perforation (CLP) in rats, which were divided into control, sham, CLP+saline, CLP+IgG (250 mg/kg, iv), and CLP+immunoglobulins enriched with immunoglobulin M (IgGAM) (250 mg/kg, iv) groups. Kidney samples were obtained in two sets of experiments to examine the early (1 day) and late (10 days) effects of treatment. Renal expression levels of C5aR, LC3A/B, and beclin-1 were measured using immunoblotting.

RESULTS:

CLP did not enhance the renal expression of autophagy markers or C5aR. Contrariwise, IgG, and IgGAM administration reduced mortality caused by the CLP procedure and significantly increased C5aR, beclin-1, and LC3A/B expression levels in kidney samples of septic rats. Surviving rats had higher renal expression levels of C5aR, beclin-1, and LC3A/B than deceased rats. Expression levels of C5aR, beclin-1, and LC3A/B showed a strong correlation during the early stage of CLP-induced sepsis but not in the late stage.

CONCLUSION:

Human-derived immunoglobulin preparations may ameliorate sepsis-related organ dysfunction partially through autophagy-related mechanisms. In the early stage of treatment, enhancement of autophagy in the kidney appears to be associated with C5aR expression.

2025-01-01·BIOCHEMICAL PHARMACOLOGY

Isoginkgetin Inhibits RANKL-induced Osteoclastogenesis and Alleviates Bone Loss

Article

作者: Zou, Jian ; Deng, Wei ; Zhou, Yi ; Wang, Bin ; Zhang, Zhida ; Tang, Kai ; Wang, Zihe ; Chen, Junchun ; Zhao, Wenhua

Osteoporosis is characterized by excessive osteoclast activity leading to bone loss, decreased bone mineral density, and increased susceptibility to fractures. Through in vivo/vitro experiments, along with network pharmacology analysis, we aimed to explore the underlying mechanisms of Isoginkgetin (IGG) in inhibiting osteoclastogenesis, providing valuable insights for further research in the future. Firstly, we ascertained the safe concentration of IGG stimulation on BMMs, followed by a systematic exploration of the concentration gradient at which IGG inhibited osteoclastogenesis using TRAP analysis. An osteoporosis model was established to further validate the in vitro experimental findings by combining Micro-CT and immunohistochemical analysis. The results show that IGG did not exhibit cytotoxicity or proliferative effects on BMMs at concentrations equal to or less than 10 μM. Additionally, IGG inhibited the activity of osteoclastogenesis and bone resorption function at lower concentrations. RT-PCR and Western Blot results demonstrated that IGG could downregulate genes and proteins associated with osteoclastogenesis. The Western Blot results also showed that IGG inhibited the phosphorylation expression of P38, ERK, and P65 in the MAPK and NF-κB pathways. At the same time, it rescued the degradation of IκB-α at 15 and 60 min. IGG can also impact the relative expression levels of oxidative proteins such as SOD-1, HO-1, and catalase, thereby influencing cellular equilibrium and stress levels, ultimately inhibiting the formation of mature OC. In vivo experiments demonstrated that IGG alleviated bone loss caused by osteoclasts and improved relevant parameters of trabecular bone. So, IGG effectively attenuated osteoclastogenesis, and improved bone density, thereby portraying its role in osteoporosis management.

2024-12-15·Immunotherapy

Customizing subcutaneous immunoglobulin administration in primary antibody deficiency: patient-centric care perspectives

Review

作者: Kreuwel, Huub ; Zekoll, Theresa ; Kobayashi, Ai Lan ; Maltese, Joanna ; Gupta, Sudhir ; Litzman, Jiří ; Kobayashi, Roger H.

This report delves into the challenges and potential solutions associated with flexible, customized subcutaneous immunoglobulin (SCIG) infusion regimens for patients with primary antibody deficiency disease (PAD). Advances in the treatment of inborn errors of immunity, particularly PAD, have converted fatal diseases into chronic, complex, long-term conditions that make adherence to treatment a critical issue. Conventional SCIG infusion regimens, while clinically effective, may not always align with the varied lifestyles, changing lifestyles and commitments of patients which can lead to missed doses, diminishing adherence thus posing potential health risks and compromising the overall effectiveness of treatment. For these reasons, it's important to develop flexible infusion regimens tailored to meet individual patient needs. Patient-centric strategies that promote shared decision-making and awareness of patient status not only promote medical efficacy but also enhance the overall patient experience. The authors of this report call attention for a need to shift toward more adaptable and individualized SCIG treatment plans for PAD patients whose needs may change over the long-term course of treatment.

36

项与 Normal Human Immunoglobulin (CSL Behring) 相关的新闻（医药）

2025-03-24

·CSL Behring

CSL全球首席执行官保罗·麦肯齐到访中国：深化中国战略布局，助力医疗健康产业高质量发展

3月下旬，全球生物治疗领域先驱CSL有限公司首席执行官兼董事总经理保罗·麦肯齐（Paul McKenzie）到访中国，参加中国发展高层论坛（CDF），并出席一系列重要的行业活动。麦肯齐此行旨在深入了解中国医疗行业的最新发展动态，探索合作机遇，并进一步践行CSL在中国市场的长期战略布局和坚定承诺。 3月23日，麦肯齐在京出席了中国发展高层论坛2025年年会，与政府领导和行业伙伴进行深入交流。作为每年全国两会后首个举办的国家级论坛，中国发展高层论坛是中国传递改革开放进展、阐释行业大政方针、促进中外交流合作的重要平台，备受国内外各界高度关注。保罗·麦肯齐在京参加中国发展高层论坛2025年年会麦肯齐表示，中国发展高层论坛是一个极具影响力的交流平台，让他深刻感受到中国对外开放的坚定决心和不懈努力。中国政府对医疗健康产业的大力支持，为CSL这样的跨国企业提供了广阔的发展空间。CSL期待进一步加强与中国业界伙伴的合作，共同推动创新医疗解决方案的落地，助力中国医疗健康事业的可持续发展。此前，在第六届国际医药创新大会（IPIF）上，麦肯齐与跨国医药企业的全球总裁和首席执行官们共聚一堂，围绕“推进监管体系现代化，促进创新药物全球同步研发”“加强创新药物知识产权保护”“完善创新药物市场准入”三个专题展开的讨论，并在相关圆桌讨论环节围绕“加速创新药物的市场准入”进行了主题发言。CSL作为历史悠久的全球医药企业，植根中国已接近40年，麦肯齐重申了CSL对中国患者的承诺，将继续深耕本土市场，与上下游伙伴携手创新，共同助力中国医疗健康事业的高质量发展。保罗·麦肯齐（Paul McKenzie） CSL有限公司首席执行官兼董事总经理中国坚持以人民为中心的发展思想，始终把改善人民生活、增进民生福祉作为出发点和落脚点，这一理念与CSL ‘以患者为中心’ 的核心价值观高度契合，也与CSL ‘致力于拯救更多患者生命并改善他们的生活质量’ 的目标一致。我们将持续推动创新研发、加快创新药的市场准入、提升药品可及性以及不断优化医药服务水平，为更多患有罕见病和严重疾病的患者提供高质量的医疗解决方案，助力 ‘健康中国2030’ 建设。 3月20日，CSL集团旗下子公司杰特贝林（CSL Behring）与国药控股于上海续签战略4PL合作协议。麦肯齐携杰特贝林亚太区商业运营高级副总裁兼总经理让·马克（Jean-Marc Morange）和中国领导团队共同出席了签约仪式。此次续约标志着双方的合作进一步升级。未来，杰特贝林将与国药控股携手，依托其全国一体化的物流网络、多元化的渠道资源、完备的商业布局以及领先的数字化营销能力，通过创新服务模式，提升杰特贝林创新疗法和药品的可及性，惠及更多中国患者。保罗·麦肯齐于上海出席杰特贝林与国药控股的签约仪式此次中国之行，麦肯齐还与杰特贝林领导团队拜访了北京协和医院以及上海瑞金医院，与医院领导及相关科室负责人展开学术交流，深入探讨了中国罕见疾病的诊疗挑战。CSL承诺与中国临床专家携手努力，积极探索在科研合作、患者服务、提升疾病认知和药品可及性等领域的合作机会，助力提升医疗服务水平，持续满足患者的未尽需求。麦肯齐的访华之旅进一步增强了CSL深耕中国市场的决心。展望未来，CSL将持续深化在罕见病和严重疾病等关键领域的本土合作，凭借深厚的专业知识与丰富的全球经验，助力医疗健康产业高质量发展，为更多中国患者带来健康福祉。关于杰特贝林以拯救生命为己任的杰特贝林是全球生物治疗领域的先驱。我们致力于以创新的科技满足患者需求，开发并生产有助于治疗免疫缺陷、凝血障碍、心血管及代谢性疾病、呼吸疾病以及移植排斥的创新药物。我们使用血浆分馏、重组蛋白技术、细胞和基因治疗三大战略科学平台，支持持续创新，不断改进产品以实现未满足的医学需求和改善患者生活质量。杰特贝林拥有全球最大的血浆收集网络之一CSL Plasma。其母公司 CSL (ASX:CSL; USOTC:CSLLY) 的总部位于澳大利亚墨尔本，拥有32,000 名员工，为全球 100 多个国家提供拯救患者性命的医疗方式。自1986年，杰特贝林就开始为中国患者提供人血白蛋白，已成为中国市场该产品的主要供应商之一。现在杰特贝林透过全资子公司广州市君信药业有限公司在中国进行销售运营，并在中国五大城市 — 上海、北京、成都、广州和武汉均设有办公室。如想了解我们对生物技术的承诺相关的更多精彩故事，请访问网站 CSLBehring.com/Vita. 了解更多信息，请参考网站内容 www.cslbehring.com.cn. 请注意，本微信平台不是向CSL Behring报告不良事件的合适平台。如您有针对CSL Behring产品的不良事件报告，请通过邮箱 phv.china@cslbehring.com 联系我们，谢谢！点击阅读原文了解更多详情

申请上市

2025-02-28

·CSL Behring

国际罕见病日｜今天，我们共同寻找生命的 “万分之一”

拖拽放大镜寻找万分之一的“非凡”人生让罕见被看见支持生命绽放更多可能参考资料： 1.https://www.csl.com/we-are-csl/vita-original-stories/2025/rare-disease-patients-need-social-connections-to-thrive 2.https://www.cslbehring.com/vita/2023/bright-ideas-for-rare-disease-day-2023 3.https://rarediseases.org/wp-content/uploads/2019/01/RDD-FAQ-2019.pdf 4.https://www.rarediseaseday.org/what-is-a-rare-disease/ 5.《中国罕见病定义研究报告2021》关于杰特贝林以拯救生命为己任的杰特贝林是全球生物治疗领域的先驱。我们致力于以创新的科技满足患者需求，开发并生产有助于治疗免疫缺陷、凝血障碍、心血管及代谢性疾病、呼吸疾病以及移植排斥的创新药物。我们使用血浆分馏、重组蛋白技术、细胞和基因治疗三大战略科学平台，支持持续创新，不断改进产品以实现未满足的医学需求和改善患者生活质量。杰特贝林拥有全球最大的血浆收集网络之一CSL Plasma。其母公司 CSL (ASX:CSL; USOTC:CSLLY) 的总部位于澳大利亚墨尔本，拥有32,000 名员工，为全球 100 多个国家提供拯救患者性命的医疗方式。自1986年，杰特贝林就开始为中国患者提供人血白蛋白，已成为中国市场该产品的主要供应商之一。现在杰特贝林透过全资子公司广州市君信药业有限公司在中国进行销售运营，并在中国五大城市 — 上海、北京、成都、广州和武汉均设有办公室。如想了解我们对生物技术的承诺相关的更多精彩故事，请访问网站 CSLBehring.com/Vita. 了解更多信息，请参考网站内容 www.cslbehring.com.cn. 请注意，本微信平台不是向CSL Behring报告不良事件的合适平台。如您有针对CSL Behring产品的不良事件报告，请通过邮箱 phv.china@cslbehring.com 联系我们，谢谢！点击阅读原文了解更多详情

基因疗法细胞疗法核酸药物

2025-02-11

·CSL Behring

CSL有限公司发布2025半年财报

2月11日，CSL有限公司公布了2025半年财务报告。 CSL有限公司首席执行官兼董事总经理Paul McKenzie先生表示：“CSL 2025财年上半年业绩表现强劲，稳健的增势将带动下半年的业务发展，长期盈利前景可期。衷心感谢全球每一位员工的不懈努力和无私奉献，你们的贡献让我感到无比自豪。展望未来，我们将保持增势，推进战略目标，持续兑现拯救患者生命、推动公共健康发展以及为股东创造更多价值的坚定承诺。” 关于杰特贝林以拯救生命为己任的杰特贝林是全球生物治疗领域的先驱。我们致力于以创新的科技满足患者需求，开发并生产有助于治疗免疫缺陷、凝血障碍、心血管及代谢性疾病、呼吸疾病以及移植排斥的创新药物。我们使用血浆分馏、重组蛋白技术、细胞和基因治疗三大战略科学平台，支持持续创新，不断改进产品以实现未满足的医学需求和改善患者生活质量。杰特贝林拥有全球最大的血浆收集网络之一CSL Plasma。其母公司 CSL (ASX:CSL; USOTC:CSLLY) 的总部位于澳大利亚墨尔本，拥有32,000 名员工，为全球 100 多个国家提供拯救患者性命的医疗方式。自1986年，杰特贝林就开始为中国患者提供人血白蛋白，已成为中国市场该产品的主要供应商之一。现在杰特贝林透过全资子公司广州市君信药业有限公司在中国进行销售运营，并在中国五大城市 — 上海、北京、成都、广州和武汉均设有办公室。如想了解我们对生物技术的承诺相关的更多精彩故事，请访问网站 CSLBehring.com/Vita. 了解更多信息，请参考网站内容 www.cslbehring.com.cn. 请注意，本微信平台不是向CSL Behring报告不良事件的合适平台。如您有针对CSL Behring产品的不良事件报告，请通过邮箱 phv.china@cslbehring.com 联系我们，谢谢！点击阅读原文了解更多详情

财报基因疗法细胞疗法

100 项与 Normal Human Immunoglobulin (CSL Behring) 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
继发性免疫缺陷	欧盟	CSL Behring GmbH	2011-04-14
继发性免疫缺陷	冰岛	CSL Behring GmbH	2011-04-14
继发性免疫缺陷	列支敦士登	CSL Behring GmbH	2011-04-14
继发性免疫缺陷	挪威	CSL Behring GmbH	2011-04-14
获得性免疫缺陷综合征	欧盟	CSL Behring GmbH	2008-04-24
获得性免疫缺陷综合征	冰岛	CSL Behring GmbH	2008-04-24
获得性免疫缺陷综合征	列支敦士登	CSL Behring GmbH	2008-04-24
获得性免疫缺陷综合征	挪威	CSL Behring GmbH	2008-04-24
丙种球蛋白缺乏血症	欧盟	CSL Behring GmbH	2008-04-24
丙种球蛋白缺乏血症	冰岛	CSL Behring GmbH	2008-04-24
丙种球蛋白缺乏血症	列支敦士登	CSL Behring GmbH	2008-04-24
丙种球蛋白缺乏血症	挪威	CSL Behring GmbH	2008-04-24
细菌感染	欧盟	CSL Behring GmbH	2008-04-24
细菌感染	冰岛	CSL Behring GmbH	2008-04-24
细菌感染	列支敦士登	CSL Behring GmbH	2008-04-24
细菌感染	挪威	CSL Behring GmbH	2008-04-24
慢性炎症性脱髓鞘性多发性神经病	美国	CSL Behring AG	2007-07-26
原发性免疫缺陷疾病	美国	CSL Behring AG	2000-07-27
免疫性血小板减少症	美国	CSL Behring AG	2000-07-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新冠肺炎后遗症	临床3期	美国	CSL Behring LLC	2024-08-28
新冠肺炎后遗症	临床3期	加拿大	CSL Behring LLC	2024-08-28
体位性心动过速综合征	临床3期	美国	CSL Behring LLC	2024-08-28
体位性心动过速综合征	临床3期	加拿大	CSL Behring LLC	2024-08-28
皮肌炎	临床3期	美国	CSL Behring LLC	2019-10-21
皮肌炎	临床3期	日本	CSL Behring LLC	2019-10-21
皮肌炎	临床3期	阿根廷	CSL Behring LLC	2019-10-21
皮肌炎	临床3期	比利时	CSL Behring LLC	2019-10-21
皮肌炎	临床3期	法国	CSL Behring LLC	2019-10-21
皮肌炎	临床3期	德国	CSL Behring LLC	2019-10-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02465359 (SCIG, CTgov)	N/A	慢性炎症性脱髓鞘性多发性神经病	15	Immune Globulin Subcutaneous (Human)	蓋顧鬱壓鬱壓餘網築壓(醖獵窪範願蓋遞壓簾獵) = 艱蓋簾顧襯艱鏇獵顧廠鹽鏇築築憲齋蓋製襯遞 (餘淵衊積鑰獵範衊窪簾, 艱鏇鑰鬱遞衊鑰醖網鏇 ~ 鏇鏇齋淵積選構構簾窪) 更多	-	2024-10-08
NCT03919773 (iSTAND, CTgov)	临床1/2期	体位性心动过速综合征	30	IVIg (Treatment IVIG Arm)	醖淵窪齋繭窪衊鹹範壓(築製襯選淵窪蓋鹹窪鑰) = 選繭鑰網鑰願獵簾構鹹網鹹鹹遞醖憲遞襯獵範 (顧鏇構選膚願襯糧簾繭, 構夢壓衊鏇壓製選壓夢 ~ 獵鑰窪蓋選糧觸醖艱鏇) 更多	-	2024-09-19
NCT03919773 (iSTAND, CTgov)	临床1/2期	体位性心动过速综合征	30	albumin (Treatment Albumin Arm)	醖淵窪齋繭窪衊鹹範壓(築製襯選淵窪蓋鹹窪鑰) = 襯窪遞積餘壓觸艱艱顧網鹹鹹遞醖憲遞襯獵範 (顧鏇構選膚願襯糧簾繭, 壓築淵壓願構製顧衊遞 ~ 糧製觸繭築鹹衊觸鑰糧) 更多	-	2024-09-19
AAAAI2024	N/A	原发性免疫缺陷疾病	-	Immune Globulin Subcutaneous 16.5%	壓簾窪鏇網襯選鑰鬱廠(壓繭鹽觸夢鑰構製蓋夢) = 觸衊鬱繭簾鑰築顧鏇鹹選夢壓願選構範簾願膚 (醖壓醖壓壓顧鏇鬱簾範 ) 更多	积极	2024-02-23
AAAAI2023	N/A	原发性免疫缺陷疾病	57	IGSC 16.5%	餘製憲積積餘獵觸願積(簾夢獵艱積餘壓積製範) = 44 bacterial RTIs were reported in 29 patients (rate of 0.77 infections/patient/year), with 1 serious 簾觸願鹽簾壓齋餘壓範 (淵廠衊鏇膚選膚願顧艱 )	-	2023-02-01
EHA2021	N/A	慢性淋巴细胞白血病	10	Subcutaneous Immunoglobulins	鹽選鹽襯餘夢鏇齋壓願(願積簾繭顧淵構構觸獵) = 範製築夢壓糧廠淵鹽憲糧觸顧夢艱齋鑰繭鹽網 (製觸醖齋鬱製夢醖顧鹽 )	-	2021-06-09
NCT04044690 (Pubmed \| Rheumatology (Oxford)) 人工标引	临床3期	肌炎一线	20	Privigen	壓夢鏇築鏇網繭廠廠壓(簾觸繭積選襯鬱鹹齋範) = 艱構窪壓憲憲鑰簾壓範網淵窪築鏇衊憲獵獵築 (齋夢鑰鹽壓顧蓋蓋齋選 ) 更多	积极	2021-04-06
NCT03593902 (CAST, CTgov)	临床2/3期	系统性硬皮病	9	Autologous Stem Cells+Mesna+Methylprednisolone+Fludarabine+CYCLOPHOSPHAMIDE+rATG+G-CSF+IVIg+Rituximab	網繭構艱簾壓積膚齋鬱(範獵簾觸憲夢築廠網觸) = 鏇繭觸蓋蓋窪艱壓鹹窪鹽積鑰夢願鬱製網遞鹹 (衊觸願鹹積鏇窪選衊築, 憲淵鏇餘構鏇鹹壓簾獵 ~ 衊醖網簾憲網窪簾膚構) 更多	-	2020-08-12
AAAAI2020	N/A	原发性免疫缺陷疾病	33	IGSC 16.5%	築蓋餘構觸遞鬱夢構顧(繭網衊窪衊網簾選鏇顧) = A total of 22/33 (67%) patients reported local-site reactions (rate 0.60/infusion), with injection pain and swelling most common. Systemic reactions were reported in 20/33 (61%) of patients (0.47/infusion), with headache and fatigue most common. Incidence of reactions was highest with the first infusion. Therapy was discontinued in one per patient request 鏇鑰構鏇鹽積壓蓋願窪 (窪鏇廠簾繭構鬱製衊觸 ) 更多	-	2020-02-01
NCT03033745 (HILO Study, AAAAI2020)	临床4期	原发性免疫缺陷疾病	16	Manual IgPro20 push infusions at high flow rate	襯鏇鏇膚願鏇遞夢選鹹(製願淵觸糧鏇構餘鏇選) = 製夢艱積鑰廠觸鑰壓簾觸鬱繭鹹積構積壓觸艱 (齋觸觸醖壓壓網襯衊鹽 )	-	2020-02-01